Goldman Sachs sold 1.3 million of the Valeant CEO's shares of his company yesterday

Embattled Canadian drug company Valeant Pharmaceutical’s CEO J. Michael Pearson got a collateral call from Goldman Sachs.

On April 22, 2014, when Valeant’s share price was $US206.93, Pearson pledged two million shares to Goldman in exchange for a $US100 million loan “that he used for, among other things, financing charitable contributions, including to Duke University, and helping to fund a community swimming pool, purchasing Valeant shares, and meeting certain tax obligations related to the vesting and payment of Valeant compensatory equity awards.”

Valeant’s share price has collapsed more than 45% in the last couple of weeks on accounting fraud allegations from a short seller and increased scrutiny around drug-price hikes.

On Thursday, Valeant’s stock closed down more than 14.3% to end at $US78.75.
The stock was up about 3% in the premarket on Friday.

Here’s the release:

Valeant Pharmaceuticals International, Inc. (NYSE: VRX) (TSX: VRX) stated today that 1,297,399 shares pledged to Goldman Sachs to secure loans made to chairman and chief executive officer J. Michael Pearson were sold by Goldman Sachs on November 5, 2015. Goldman Sachs held the shares as collateral for loans extended to Pearson.

As disclosed in the company’s proxy statement filed on April 22, 2014, the company’s board permitted Pearson to pledge approximately two million shares. As of the company’s most recent proxy statement, filed April 9, 2015, those shares represent approximately 20.19% of his shares beneficially owned. Pearson pledged those shares to Goldman Sachs as collateral for loans of approximately $US100 million that he used for, among other things, financing charitable contributions, including to Duke University, and helping to fund a community swimming pool, purchasing Valeant shares, and meeting certain tax obligations related to the vesting and payment of Valeant compensatory equity awards. Goldman Sachs required repayment of the loans, and has informed the company that it sold the shares it held as collateral in satisfaction of the loans. After repayment of the loans with the proceeds from the sale by Goldman Sachs, the loan agreements will terminate and there will be no amounts outstanding under those agreements.

“Since joining Valeant, I have not sold any shares provided to me as compensation, and it was not my desire that shares be sold now,” Pearson said. “I have complete confidence in Valeant’s ability to move forward and continue meeting our commitments to patients, doctors, and shareholders.”

In January 2015, Pearson agreed to not receive a base salary and instead be compensated exclusively through cash and stock incentive awards tied to performance.

NOW WATCH: This is what will happen when the Fed raises rates

NOW WATCH: Money & Markets videos

Business Insider Emails & Alerts

Site highlights each day to your inbox.

Follow Business Insider Australia on Facebook, Twitter, LinkedIn, and Instagram.